Related Experiment Videos
[Intralesional Pingyangmycin therapy for 51 infantile patients with parotid gland hemangiomas]
Li-Li Wang1, Qing-Hong Gao, Kun Liu
1Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Insights
Intralesional Pingyangmycin (PYM) therapy effectively treats infantile parotid gland hemangiomas, with over 82% achieving complete resolution. This method shows promise as a primary treatment option with minimal side effects.
Area of Science:
- Pediatric Otolaryngology
- Vascular Anomalies
- Interventional Oncology
Background:
- Parotid gland hemangiomas are common benign vascular tumors in infants.
- Treatment options for parotid hemangiomas can be challenging due to the gland's location and functional importance.
- Intralesional therapy offers a targeted approach to managing these lesions.
Purpose of the Study:
- To evaluate the efficacy and safety of intralesional Pingyangmycin (PYM) for treating parotid gland hemangiomas in children.
- To determine the optimal therapeutic approach for infantile parotid hemangiomas.
Main Methods:
- Retrospective analysis of 51 infantile patients with parotid hemangiomas treated with intralesional PYM and dexamethasone.
- Dosage and administration details of PYM injections were recorded.
- Treatment outcomes were compared based on tumor size.
Main Results:
- Complete resolution was observed in 82.35% of patients, with good cosmetic outcomes.
- Partial regression occurred in 15.69%, and 1.96% showed no change.
- No significant adverse events like pulmonary fibrosis or growth inhibition were reported.
Conclusions:
- Intralesional Pingyangmycin (PYM) therapy is a viable and effective primary treatment for parotid gland hemangiomas in infants.
- Ultrasonography is recommended for diagnosis and guiding treatment of these lesions.
Purpose:
To investigate the indication and outcome of intralesional Pingyangmycin (PYM) therapy for parotid gland hemangiomas in early childhood.
Methods:
51 infantile patients with hemangiomas in the parotid gland were studied retrospectively, which had been treated in the clinic of West China Hospital of Stomatology, Sichuan University during the 15-year period from May 1990 to May 2005. In this study, 21 were male, 30 were female, and the ratio of male to female was 1:1.43. The age of the children ranged from 6 months to 4 years, with an average age of 10 months. 38 were deep-seated hemangiomas, and 13 were mixed hemangiomas. 27 were in the right parotid gland and 24 in the left, no bilateral case. All the patients underwent intralesional injection of a solution of 8 mg PYM in 8 mL normal saline mixed with 5 mg dexamethasone. The total dose of PYM ranged from 20mg to 35 mg, which was administered 0.5 or 1 mg per injection. SPSS10.0 software package was used to compare the treatment efficacy between the patients with hemangioma <4 cm in diameter and >or=4 cm in diameter.
Results:
Hemangiomas of 42 cases (82.35%) showed complete resolution with good appearance, 8 cases (15.69%) were partly regressed, and 1 case (1.96%) had no obvious size change. No serious side effects were seen, such as pulmonary fibrosis and growth inhibition. No significant correlation was found between treatment efficacy and tumor size.
Conclusion:
Intralesional PYM therapy maybe is a selective primary therapy option for parotid gland hemangioma, and ultrasonography should be useful for diagnosis and treatment of this lesion.